Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064587 | 0.92 | HSD17B14 (0.45) | KMT2AKDM4EPIM1HSD17B14METAP2 | |
| SCHEMBL3825336 | 0.86 | KDM4E (0.53) | KMT2AKDM4EPIM1HSD17B14METAP2 | |
| SCHEMBL3860500 | 0.80 | HSD17B14 (0.52) | KDM4EHSD17B14ALDH1A1TSHRHDAC8 | |
| SCHEMBL7243815 | 0.76 | PIM1 (0.57) | KDM4EPIM1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL6430262 | 0.72 | KDM4E (0.50) | KMT2AKDM4EPIM1METAP2PLAU | |
| SCHEMBL28153888 | 0.71 | KMT2A (0.47) | KMT2AKDM4EPIM1METAP2PLAU | |
| SCHEMBL6434016 | 0.71 | KDM4E (0.49) | KMT2AKDM4EPIM1METAP2PLAU | |
| SCHEMBL5468569 | 0.70 | CA12 (0.54) | KDM4EHSD17B10PDE4DHTTL3MBTL1 | |
| SCHEMBL7245263 | 0.70 | PTPN1 (0.44) | KMT2AKDM4EHSD17B14ALDH1A1HPGD | |
| SCHEMBL1507703 | 0.70 | KDM4E (0.76) | KMT2AKDM4EPIM1METAP2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975597-B1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2009-09-02 | — | — | EP | claimed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | claimed |
| EP-0975597-B1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | disclosed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | disclosed |
| EP-0975597-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045269-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | KMT2A 1290/4885KDM4E 2169/4885PIM1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.